drugset
drugset / Trial / NCT00305773

Vorinostat in Treating Patients With Acute Myeloid Leukemia

NCT00305773 ↗

Phase 2 Completed 37 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupOpen-labelTreatment

Summary

Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for their growth. Giving the drug in different ways may kill more cancer cells. This randomized phase II trial is studying two different schedules of vorinostat to see how well they work in treating patients with acute myeloid leukemia.

Timeline

Start
2006-01
Primary completion
2009-05
Completion
2010-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vorinostat Small molecule 200 mg Oral
Subject Vorinostat Small molecule 400 mg Oral

Indications

acute erythroid leukemia acute megakaryoblastic leukemia in adult acute myeloblastic leukemia with maturation acute myeloblastic leukemia without maturation acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with minimal differentiation acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) acute myelomonocytic leukemia M4 acute promyelocytic leukemia adult acute monocytic leukemia myelodysplastic syndrome with multilineage dysplasia